Mindset Pharma (CNSX:MSET) - Hisse Senedi Fiyatı, Haberler ve Analizler

MSET Stoklara Genel Bakış

Mindset Pharma Inc. develops and sells psychedelic medicines to treat neurological and psychiatric disorders in Canada. Daha fazla detay

MSET temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	2/6
Temettüler	0/6

Ödüller

Gelirin yılda 43.75% oranında artması öngörülüyor

Gelir, geçen yıl 242.5% oranında arttı

Risk Analizi

Önümüzdeki 3 yıl boyunca kazançların yılda ortalama 22% oranında düşmesi öngörülüyor

Negatif hissedar öz sermayesi

1 yıldan az nakit akışı var

Anlamlı bir piyasa değeri yok ( CA$75M )

+ 2 daha fazla risk

Mindset Pharma Inc. Rakipler

InnoCan Pharma

CNSX:INNO

CA$60.3m

1CM

CNSX:EPIC

CA$29.4m

YourWay Cannabis Brands

CNSX:YOUR

CA$23.2m

Simply Better Brands

TSXV:SBBC

CA$76.9m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Mindset Pharma
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	CA$0.74
52 Haftanın En Yüksek Seviyesi	CA$0.75
52 Haftanın En Düşük Seviyesi	CA$0.22
Beta	-0.098
11 Aylık Değişim	1.37%
3 Aylık Değişim	45.10%
1 Yıllık Değişim	76.19%
33 Yıllık Değişim	n/a
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-26.00%

Son Haberler & Güncellemeler

Is Mindset Pharma (CSE:MSET) In A Good Position To Deliver On Growth Plans?

Jun 02

Recent updates

Is Mindset Pharma (CSE:MSET) In A Good Position To Deliver On Growth Plans?

Jun 02

Companies Like Mindset Pharma (CSE:MSET) Can Afford To Invest In Growth

Sep 18

We're Interested To See How Mindset Pharma (CSE:MSET) Uses Its Cash Hoard To Grow

Jun 05

Hissedar Getirileri

	MSET	CA Pharmaceuticals	CA Pazar
7D	-1.3%	-5.2%	1.3%
1Y	76.2%	-23.4%	23.1%

Getiri vs. Endüstri: MSET geçen yıl % -23.4 oranında getiri sağlayan Canadian Pharmaceuticals sektörünü aştı.

Getiri vs Piyasa: MSET geçen yıl % 23.1 oranında getiri sağlayan Canadian Piyasasını aştı.

Fiyat Oynaklığı

Is MSET's price volatile compared to industry and market?
MSET volatility
MSET Average Weekly Movement	6.6%
Pharmaceuticals Industry Average Movement	12.0%
Market Average Movement	8.3%
10% most volatile stocks in CA Market	17.8%
10% least volatile stocks in CA Market	2.9%

İstikrarlı Hisse Senedi Fiyatı: MSET hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: MSET 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 13% dan 7% a düştü.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
n/a	n/a	James Lanthier	www.mindsetpharma.com

Mindset Pharma Inc. Temel Bilgiler Özeti

Mindset Pharma'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
MSET temel i̇stati̇sti̇kler
Piyasa değeri	CA$74.96m
Kazançlar(TTM)	-CA$6.11m
Gelir(TTM)	CA$7.75m

9.7x

P/S Oranı

-12.3x

F/K Oranı

MSET aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
MSET gelir tablosu (TTM)
Gelir	CA$7.75m
Gelir Maliyeti	CA$0
Brüt Kâr	CA$7.75m
Diğer Giderler	CA$13.86m
Kazançlar	-CA$6.11m

Son Raporlanan Kazançlar

Mar 31, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.06
Brüt Marj	100.00%
Net Kâr Marjı	-78.82%
Borç/Özkaynak Oranı	0%

MSET uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

MSET Stoklara Genel Bakış

Ödüller

Risk Analizi

Mindset Pharma Inc. Rakipler

CNSX:INNO

CA$60.3m

CNSX:EPIC

CA$29.4m

CNSX:YOUR

CA$23.2m

TSXV:SBBC

CA$76.9m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Otsuka America, Inc. completed the acquisition of Mindset Pharma Inc. (CNSX:MSET).

Otsuka America, Inc. entered into a definitive agreement to acquire Mindset Pharma Inc. (CNSX:MSET) for CAD 80 million.

Otsuka America, Inc. entered into a definitive agreement to acquire Mindset Pharma Inc. (CNSX:MSET) for CAD 80 million.

New major risk - Financial position

Is Mindset Pharma (CSE:MSET) In A Good Position To Deliver On Growth Plans?

Mindset Pharma Inc., Annual General Meeting, Mar 17, 2023

Recent updates

Otsuka America, Inc. completed the acquisition of Mindset Pharma Inc. (CNSX:MSET).

Otsuka America, Inc. entered into a definitive agreement to acquire Mindset Pharma Inc. (CNSX:MSET) for CAD 80 million.

Otsuka America, Inc. entered into a definitive agreement to acquire Mindset Pharma Inc. (CNSX:MSET) for CAD 80 million.

New major risk - Financial position

Is Mindset Pharma (CSE:MSET) In A Good Position To Deliver On Growth Plans?

Mindset Pharma Inc., Annual General Meeting, Mar 17, 2023

Mindset Pharma Receives Another Allowance from USPTO for Patent Application Expanding Composition of Matter for Family 1 Psilocybin Analogs

Mindset Pharma Inc. Receives Allowance for U.S. Patent Application Covering Composition of Matter for Its Lead Psychedelic Therapeutic Candidate

Mindset Pharma Inc., Annual General Meeting, Feb 24, 2023

High number of new and inexperienced directors

Mindset Pharma Presents Poster At Neuroscience 2022 Highlighting Preclinical Data on MSP-1014, Its Psilocybin-Like Lead Drug Candidate

Mindset Pharma Inc. Selects Lead Clinical Candidates From “Family 2” of its Next Generation Psychedelic Drug Portfolio

Companies Like Mindset Pharma (CSE:MSET) Can Afford To Invest In Growth

Mindset Pharma Inc. Receives Scientific Advice from UK Regulator Facilitating Advancement of Phase 1 First-In-Human Clinical Trial Plan for Its Lead Clinical Candidate, MSP-1014

Mindset Pharma Files National Patents Protecting Family 1 Application in 16 Different Countries

Mindset Pharma Inc. Announces it Further Expands its IP Portfolio with Three Additional Non-Tryptamine Families of Next-Generation Psychedelic Compounds

High number of new and inexperienced directors

Mindset Pharma Inc. Announces Development of Novel, Optimized, Intranasal Formulation

We're Interested To See How Mindset Pharma (CSE:MSET) Uses Its Cash Hoard To Grow

Mindset Pharma Inc. Progresses Plans for Clinical Trials of Its Advanced Pre-Clinical Psychedelic, Msp-1014

Independent Chairman recently bought CA$52k worth of stock

Mindset Pharma Strengthens IP Portfolio with Another New Provisional Patent Application Covering its Next-Generation DMT and 5-MeO-DMT Drug Candidate Compounds

Mindset Pharma Inc Identifies New Pharmacological Insights of First Generation Psychedelics Through its COPE Program with InterVivo Solutions

Mindset Pharma Inc Appoints Fiona Randall as Senior Vice President of External Alliances and Scientific Strategy

Independent Chairman recently bought CA$102k worth of stock

Mindset Pharma Inc. announced that it has received $5 million in funding from McQuade Center for Strategic Research and Development, LLC

Mindset Pharma Announces Filing of International Patent Application Covering its Family 3 “Microdose” Compounds

Mindset Pharma Announces Preclinical Results Demonstrating Extended Duration of Action in Its Long-Acting Next Generation Psychedelic Compounds

Mindset Pharma Inc. Files its New Provisional Patent Application with the United States Patent and Trademark Office Extending its Family 4 Compounds, Set of Novel DMT/5-MeO-DMT Analogs

Mindset Pharma Inc. Files International Patent Application for Its Novel Psilocybin Synthesis Method

Chairman & Director recently bought CA$66k worth of stock

Mindset Selects its Lead Clinical Candidate, MSP-1014, a Next Generation Psychedelic Medicine

Director recently bought CA$75k worth of stock

Mindset Pharma Inc. Files Sixth U.S. Provisional Patent, Expanding its Psychedelic Drug Candidates Pipeline with Novel DMT & 5-MeO-DMT Analogs

Mindset Pharma Inc. Appoints Joseph Gabriele to Scientific Advisory Board

Mindset Pharma Reaches Agreement to Manufacture Large Quantity of Pharmaceutical Grade Psilocybin Using Patent-Pending Synthesis Process

Mindset Pharma Inc. Announces New Drug Program with Proof-Of-Concept Animal Studies of its Patent-Pending Psilocybin-Inspired Drug Candidates

Mindset Selects Compounds from Its Third Psilocybin-Inspired Drug Family to Move into in Vivo Poc Studies

Mindset Pharma Inc. Expands Portfolio of Psychedelic Drug Candidates with Third U.S. Provisional Patent Application

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

Mindset Pharma Inc. Temel Bilgiler Özeti

9.7x

-12.3x

Kazanç ve Gelir